#CAR-T

Oricell Therapeutics has added another $40 million to what it describes as a pre-IPO financing, taking total funds raised past $110 million. The company is focused on CAR-T therapies for solid tumors.

Doctors in Germany report that a CAR-T treatment sent three severe autoimmune diseases into sustained remission in a 47-year-old woman after years of failed therapies.

A small phase 1 study in relapsed or refractory multiple myeloma reports that anti-BCMA CAR-T cells can be generated inside the body after a single infusion, potentially bypassing several steps that usually slow access.

Researchers are pairing lab-grown insulin cells with engineered immune bodyguards that prevent rejection — potentially eliminating the need for lifelong immunosuppression.